botulism immune globulin IV (Rx)

Brand and Other Names:BabyBIG

Dosing & Uses

AdultPediatric

Not indicated for adults

Dosage Forms & Strengths

powder for injection-preservative free

  • 100mg/vial

Infant Botulism

Indicated for treatment of infant botulism caused by toxin type A or B in patients aged <1 year

≥1 year: Not indicated

<1 year: 50 mg/kg (ie, 1 mL/kg) IV infusion; infuse at 25 mg/kg/hr for the first 15 minutes; if well tolerated may increase rate to 50 mg/kg/hr  

Titer of antibodies in reconstituted product against type A botulinum toxin is at least 15 IU/mL and against type B toxin is at least 2.7 IU/mL

Renal Impairment

Minimize rate of infusion and concentration

Next:

Adverse Effects

>10%

Transient increase in blood pressure

Pallor Edema

Transient decrease in blood pressure

Cardiac murmur

Irritability

Pyrexia

Decrease in body temperature

Contact dermatitis

Erythematous rash

Dysphagia

Loose stools

Vomiting

Abdominal distension

Otitis media

Atelectasis

Rhonchi

Nasal congestion

Decrease in oxygen saturation

Cough

Rales

1-10%

Tachycardia

Peripheral coldness

Central nervous system agitation

Dehydration

Hyponatremia

Metabolic acidosis

Decrease in hemoglobin

Local injection site reaction

Injection site erythema

Neurogenic bladder

Decrease in breath sounds

Stridor

Lower respiratory tract infection

Dyspnea

Tachypnea

Oral candidiasis

Infusion rate reactions

Postmarketing Reports

Retrospective publications have shown safety-related information consistent with the safety-related information in the approved product labeling, and no new safety-related information has been presented

Previous
Next:

Warnings

Contraindications

Documented hypersensitivity; selective immunoglobulin A deficiency

Cautions

Aseptic meningitis syndrome reported

Acute renal dysfunction may occur

Assess renal function prior to and following administration

Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving IGIV therapy

Hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration

The product is made from human plasma and may contain infectious agents (eg, viruses and, theoretically, Creutzfeldt-Jakob disease)

Patients should not be volume depleted (hypovolemic) before therapy

For IV infusion only; do not exceed recommended rate of administration

Previous
Next:

Pregnancy & Lactation

Not indicated for adults

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Derived from plasma of adults immunized with botulinum toxoid types A and B; provides antibodies to neutralize circulating toxins

Pharmacokinetics

Half-life elimination: 28 Days

Duration: 6 months (protective levels of neutralizing antibodies)

Previous
Next:

Administration

IV Compatibilities

0.9% NaCl

Dextrose solutions (with or without NaCl added), including the following concentrations: 2.5%, 5%,10%, or 20%

IV Preparation

100 mg ± 20 mg lyophilized immunoglobulin per single-dose vial

Reconstitute lyophilized powder

  • Reconstitute with 2 mL of sterile water for injection to obtain 50 mg/mL solution
  • A double-ended transfer needle or large syringe is suitable for adding the water for reconstitution
  • When using a double-ended transfer needle, insert one end first into the vial of water
  • Lyophilized powder is supplied in an evacuated vial; therefore, the water should transfer by suction (the jet of water should be aimed to the side of the vial)
  • After water is transferred into vial, residual vacuum should be released to hasten the dissolution
  • Rotate viral gently to wet all the powder
  • ~30-minute interval should be allowed to completely dissolve powder
  • DO NOT shake vial, as this will cause foaming
  • Inspect visually for particulate matter and discoloration before administration
  • Infuse solution only if it is colorless, free of particulate matter, and not turbid
  • To prevent the transmission of hepatitis viruses or other infectious agents from one person to another, use sterile disposable syringes and needles
  • Never reuse syringes and needles

IV Administration

Do not predilute before infusion

Begin infusion within 2 hr after reconstitution is complete and conclude within 4 hr of reconstitution, unless infusion is temporarily interrupted for adverse reaction

Monitor vital signs continuously during infusion

Administer IV using low volume tubing and a constant infusion pump (ie, an IVAC pump or equivalent) through a separate IV line

If a pre-existing line must be used, do not dilute reconstituted solution more than 1:2 with any of the compatible solutions

Storage

Store unopened vial containing lyophilized product between 2-8ºC (35.6-46.4ºF)

Do not store in the reconstituted state

Use reconstituted solution within 2 hr

Do not use beyond expiration date, and dispose unused product in accordance with local requirements

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.